If you have been reading about anti-doping analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Film laboratories or darkrooms Clandestine labs for the production of illegal drugs Computer labs Crime labs used to process crime scene evidence Language labs Medical labs (involves handling of chemical compounds) Public health labs Cleanrooms
All chemical elements derive from stellar nucleosynthesis except for hydrogen and some helium and lithium. Basic chemical ingredients of life – the carbon–hydrogen molecule (CH), the carbon–hydrogen positive ion (CH+) and the carbon ion (C+) – can be produced by ultraviolet light from stars. Complex molecules, including organic molecules, form naturally both in space and on planets. Organic molecules on the early Earth could have had either terrestrial origins, with organic molecule synthesis driven by impact shocks or by other energy sources, such as ultraviolet light, redox coupling, or electrical discharges; or extraterrestrial origins (pseudo-panspermia), with organic molecules formed in interstellar dust clouds or in the solar nebula accumulating onto the planet.
Involvement of lipid peroxidation chain reaction in atherogenesis triggered research on the protective role of the heavy isotope (deuterated) polyunsaturated fatty acids (D-PUFAs) that are less prone to oxidation than ordinary PUFAs (H-PUFAs). PUFAs are essential nutrients – they are involved in metabolism in that very form as they are consumed with food. In transgenic mice, a model for human-like lipoprotein metabolism, adding D-PUFAs to the diet reduced body weight gain, improved cholesterol handling, and reduced atherosclerotic damage to the aorta.
Collagen is a structural protein, often referred to as "the steel of biological materials". There are multiple types of collagen: Type I (comprising skin, tendons and ligaments, vasculature and organs, as well as teeth and bone and artery walls); Type II (a component in cartilage); Type III (often found in reticular fibers); and others. Collagen has a hierarchical structure, forming triple helices, fibrils, and fibers. Collagen are a family of protein that support and strengthen many tissues in the body.
Several diseases can affect cartilage. Chondrodystrophies are a group of diseases, characterized by the disturbance of growth and subsequent ossification of cartilage. Some common diseases that affect the cartilage are listed below.
Sources: en.wikipedia.org
Per Mendeleev's nomenclature for unnamed and undiscovered elements, flerovium is sometimes called eka-lead. In 1979, IUPAC published recommendations according to which the element was to be called ununquadium (symbol Uuq), a systematic element name as a placeholder, until the discovery of the element is confirmed and a permanent name is decided on. Most scientists in the field called it "element 114", with the symbol of E114, (114) or 114. Per IUPAC recommendations, the discoverer(s) of a new element has the right to suggest a name. After IUPAC recognized the discovery of flerovium and livermorium on 1 June 2011, IUPAC asked the discovery team at JINR to suggest permanent names for the two elements. The Dubna team chose the name flerovium (symbol Fl), after Russia's Flerov Laboratory of Nuclear Reactions (FLNR), named after Soviet physicist Georgy Flyorov (also spelled Flerov); earlier reports claim the element name was directly proposed to honour Flyorov. In accordance with the proposal received from the discoverers, IUPAC officially named flerovium after Flerov Laboratory of Nuclear Reactions, not after Flyorov himself. Flyorov is known for writing to Joseph Stalin in April 1942 and pointing out the silence in scientific journals in the field of nuclear fission in the United States, Great Britain, and Germany. Flyorov deduced that this research must have become classified information in those countries. Flyorov's work and urgings led to the development of the USSR's own atomic bomb project.
Admiral Brad Cooper said that the US military had struck more than 8,000 Iranian military targets, including 130 vessels. On 21 March, the US conducted strikes on the Natanz Nuclear Facility using bunker buster bombs to target the site. Russia condemned the strikes on Natanz as a "blatant violation of international law" while the IAEA urged military restraint "to avoid any risk of a nuclear accident". In response, Iran struck the southern Israeli town of Dimona, injuring at least 78 people. Iran said that it targeted the Shimon Peres Negev Nuclear Research Center. Citing unnamed US officials, CNN and The Wall Street Journal reported that Iran unsuccessfully attempted to strike the joint US–UK military base at Diego Garcia on the Chagos Islands in the British Indian Ocean Territory. The report said one of the missiles broke apart mid-flight, while another was intercepted by a SM-3 air defense missile launched by a US warship. Israel said that Iran used a two-stage intercontinental ballistic missile to target the island. Iran denied launching missiles towards Diego Garcia, saying that it was an Israeli false flag attack. In response the UK foreign secretary confirmed and denounced the Iranian attack on their end, and additionally expanded permission for the United States to bomb certain targets using their bases. No evidence has been presented that the alleged Iranian missiles neared Diego Garcia or that one was intercepted.
Magoulick & Marshall (2026) interpret lack of dispersal of pronghorns into South America during the Great American Interchange as most likely linked to lack to suitable climatic conditions in potential dispersal corridors. A study on the limb bone histology and life history of Ampelomeryx ginsburgi is published by Viladot et al. (2026). Quaranta et al. (2026) reconstruct the biogeographical history of giraffids on the basis of the Miocene to Holocene fossil record. Al Riaydh et al. (2026) study the assemblage of giraffid astragali from upper Miocene-Pliocene As-Sahabi deposits (Libya), and identify fossil material of two species of Samotherium (S. major and S. boissieri) that likely differed in habitat preferences. Tsatsalis & van der Geer (2026) reconstruct life histories of Pleistocene Axis lydekkeri and Duboisia santeng from Java (Indonesia), reporting evidence of high juvenile mortality and evidence of survival after senescence. Evidence from the study of the isotopic composition of tooth enamel of deer and Alpine ibex from the Melitzia Cave (Greece), indicative of presence of a Late Pleistocene refugium in the Mani Peninsula, is presented by Tzortzi et al. (2026). Evidence of a flexible dietary niche of reindeer living in Europe from Marine Isotope Stage 5a to Marine Isotope Stage 2 is presented by Hemmingham, Pappa & Schreve (2026). New fossil material of Sinomegaceros ordosianus, providing new information on the morphology of members of this species, is described from the Pleistocene strata from the Yitong River basin (China) by Zhang & Wang (2026).
In one form of dialysis, called peritoneal dialysis, a glucose solution is sent through a tube into the peritoneal cavity. The fluid is left there for a prescribed amount of time to absorb waste products, and then removed through the tube. The reason for this effect is the high number of arteries and veins in the peritoneal cavity. Through the mechanism of diffusion, waste products are removed from the blood.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.